LY2886721
4 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
4
Ongoing
0
Recruiting
0
Completed
3
Sites
36
Countries
5
Endpoints
56
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 56 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 6 of 56 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
2
2
2
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
4 of 4
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT01561430Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease | LY2886721 Alzheimer’s disease, MCI / preclinical Alzheimer’s | MCI due to AD | Ph 1/2 | Terminated | 34 | Aug 2013 | - | results |
| NCT01227252A Safety Study of LY2886721 Multiple Doses in Healthy Subjects | LY2886721 Alzheimer’s disease | Age ≥20 | Ph 1 | Completed | 1 | Apr 2011 | - | results |
| NCT01807026A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease | LY2886721 Alzheimer’s disease | Alzheimer's disease | Ph 1 | Completed | 1 | May 2013 | - | results |
| NCT01133405A Safety Study of LY2886721 Single Doses in Healthy Subjects | LY2886721 Alzheimer’s disease | Age ≥20 | Ph 1 | Completed | 1 | Oct 2010 | - | results |
Showing 1-4 of 4 trials